Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment
- PMID: 19269033
- DOI: 10.1016/j.ophtha.2008.11.005
Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment
Abstract
Purpose: To investigate the feasibility and efficacy of microincision vitrectomy surgery (MIVS) combined with intravitreal bevacizumab (IVB) as a surgical adjunct for treating traction retinal detachment (TRD) secondary to severe proliferative diabetic retinopathy (PDR).
Design: Retrospective, comparative, consecutive, interventional case series.
Participants: Seventy-one eyes of 59 consecutive patients who underwent primary vitrectomy for diabetic TRD and were followed up for more than 6 months after surgery.
Methods: Eyes that received IVB (1 mg) as a preoperative adjunct followed by MIVS (IVB/MIVS group) from November 2005 through December 2007 were compared with eyes that underwent conventional 20-gauge pars plana vitrectomy (20-g PPV group) from September 2003 through October 2005.
Main outcome measures: Primary and ultimate anatomic success, intraoperative and postoperative complications, and final visual success with at least 6 months of follow-up.
Results: This series included 38 eyes (33 patients) in the IVB/MIVS group and 33 eyes (26 patients) in the 20-g PPV group. The primary and ultimate anatomic success rates (95% vs. 91% and 100% in both groups, respectively) and the mean visual acuity changes did not differ significantly between groups; the surgical time and intraoperative bleeding in the IVB/MIVS group decreased significantly compared with the 20-g PPV group (P<0.001). The rate of visual improvement of 3 lines or more at the 6-month follow-up was 68% in the IVB/MIVS group and 49% in the 20-g PPV group, respectively. Progression of the preexisting TRD after IVB occurred in 7 eyes (18%). Absence of previous laser photocoagulation (P = 0.025) and the presence of a ring-shaped fibrovascular membrane (P = 0.013) were relevant findings in eyes with these IVB-induced complications.
Conclusions: Intravitreal bevacizumab plus MIVS offers comparable anatomic success compared with conventional 20-gauge PPV in patients with TRD resulting from severe PDR. This technique shortens the surgical time with fewer intraoperative complications and favorable visual recovery. However, caution should be taken because of rapid progression of the preexisting TRD after IVB in some patients.
Financial disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Similar articles
-
Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.Ophthalmology. 2009 Oct;116(10):1943-8. doi: 10.1016/j.ophtha.2009.07.001. Epub 2009 Aug 21. Ophthalmology. 2009. PMID: 19699531 Clinical Trial.
-
The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.Ophthalmology. 2011 Nov;118(11):2218-26. doi: 10.1016/j.ophtha.2011.03.036. Epub 2011 Jul 2. Ophthalmology. 2011. PMID: 21724263 Clinical Trial.
-
A 27-gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery.Ophthalmology. 2010 Jan;117(1):93-102.e2. doi: 10.1016/j.ophtha.2009.06.043. Epub 2009 Oct 31. Ophthalmology. 2010. PMID: 19880185
-
A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy.Br J Ophthalmol. 2011 Sep;95(9):1216-22. doi: 10.1136/bjo.2010.189514. Epub 2011 Jan 27. Br J Ophthalmol. 2011. PMID: 21278146 Free PMC article. Review.
-
Surgical management of retinal diseases: proliferative diabetic retinopathy and traction retinal detachment.Dev Ophthalmol. 2014;54:196-203. doi: 10.1159/000360467. Epub 2014 Aug 26. Dev Ophthalmol. 2014. PMID: 25196770 Review.
Cited by
-
Comparison of 27-gauge beveled-tip and 25-gauge flat-tip microincision vitrectomy surgery in the treatment of proliferative diabetic retinopathy: a randomized controlled trial.BMC Ophthalmol. 2023 Dec 12;23(1):504. doi: 10.1186/s12886-023-03251-2. BMC Ophthalmol. 2023. PMID: 38087284 Free PMC article. Clinical Trial.
-
Vitreous Levels of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Patients with Proliferative Diabetic Retinopathy: A Clinical Correlation.Biomolecules. 2023 Nov 8;13(11):1630. doi: 10.3390/biom13111630. Biomolecules. 2023. PMID: 38002312 Free PMC article.
-
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4. Cochrane Database Syst Rev. 2023. PMID: 37260074 Review.
-
Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023.Int J Retina Vitreous. 2023 Apr 18;9(1):29. doi: 10.1186/s40942-023-00467-8. Int J Retina Vitreous. 2023. PMID: 37072797 Free PMC article.
-
Post-vitrectomy delayed retinal breaks in proliferative diabetic retinopathy.Int J Retina Vitreous. 2023 Feb 1;9(1):7. doi: 10.1186/s40942-023-00444-1. Int J Retina Vitreous. 2023. PMID: 36726158 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
